Colostrum
Bovine colostrum is the first milk produced 24-72 hours postpartum, loaded with immunoglobulins, growth factors, and lactoferrin. Jones 2016 systematic review (Sports Med) and Davison 2021 meta-analysis show 40-50% reduction in upper respiratory illness in exercise-stressed athletes at 20 g/day; Halasa 2017 documented gut permeability protection.
Colostrum scored 6.7 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Vitamin / Mineral / Nutrient.
What It Is
Bovine colostrum is the first milk produced by cows in the 24-72 hours after birth, containing dramatically higher concentrations of immunoglobulins (IgG 20-200 mg/mL), lactoferrin (1.5-5 mg/mL), growth factors (IGF-1 100-2000 ug/L, TGF-beta, EGF), and proline-rich polypeptides (PRPs) compared to mature milk. These bioactives survive partial gastric digestion and act primarily in the gut lumen, supporting mucosal immunity and epithelial barrier integrity.
Type: Nutrient supplement (bovine colostrum; bioactive immunoglobulin + growth factor + lactoferrin rich complex).
Current status: Available as a dietary supplement (OTC). Not standardized for IgG content across brands. ARMRA, Kion, Sovereign Laboratories, and generic products vary widely in concentration, processing (spray-dried vs flash-pasteurized), and sourcing quality.
Terminology
- IgG: Immunoglobulin G, the most abundant antibody class; in colostrum it provides passive gut-lumen immunity against pathogens.
- IgA: Immunoglobulin A, the primary mucosal antibody class, concentrated at gut and respiratory epithelia.
- Lactoferrin: Iron-binding glycoprotein in colostrum and whey; antimicrobial via iron sequestration and immunomodulatory.
- PRP: Proline-Rich Polypeptide, a class of small colostral peptides that modulate cytokine production and immune signaling.
- TGF-beta: Transforming Growth Factor beta, regulates epithelial cell proliferation, tight-junction integrity, and immune tolerance.
- IGF-1: Insulin-like Growth Factor 1, present in colostrum but degraded in digestion, so oral dosing does NOT raise systemic IGF-1.
- LGG: Lactobacillus rhamnosus GG, a probiotic strain sometimes stacked with colostrum for gut-barrier work.
- URI: Upper Respiratory Illness, the primary clinical endpoint in colostrum athlete trials.
- Leaky gut: Colloquial term for increased intestinal permeability, measurable via lactulose:mannitol ratio, zonulin, or serum LPS.
- First-day colostrum: True colostrum produced in the first 24 hours postpartum, with the highest IgG and growth-factor concentrations.
- Transitional milk: The milk produced roughly 2-5 days postpartum, with declining bioactive concentration as it transitions toward mature milk.
- Bovine: Derived from cows (Bos taurus), as distinct from caprine (goat), ovine (sheep), or human colostrum.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 3 routes and 4 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral powder (mixed in water/smoothie) | 10-60 g/day | 1-20 g/day (brand-dependent) | |
| Oral capsule | 20-40 capsules/day to reach 10-20 g | 4-12 capsules/day (most community protocols) | |
| Oral liquid | Limited direct RCT data; extrapolated from powder equivalents | 1-2 tablespoons/day (product-dependent) |
Protocols
Athletic recovery (heavy training blocks) Clinical
- Dose
- 20 g/day powder, split AM/PM
- Frequency
- daily
- Duration
- minimum 8-12 weeks; throughout training block
Based on Jones 2014, 2015 URI reduction trials and Shing 2007 salivary IgA maintenance. IgG-standardized product recommended (minimum 20-30% IgG by weight). Start 2 weeks before training intensification.
Gut health / leaky gut support Clinical
- Dose
- 20 g/day powder
- Frequency
- daily
- Duration
- 12-16 weeks, then reassess
Based on Marchbank 2011 and Halasa 2017; prevents NSAID-induced and exercise-induced gut permeability increase. Consider stacking with L-glutamine, deglycyrrhizinated licorice, and dietary polyphenols.
Immune prophylaxis (sick season) Anecdotal + clinical extrapolation
- Dose
- 10-20 g/day powder
- Frequency
- daily during cold/flu season (typically October-March)
- Duration
- seasonal
Extrapolated from Jones 2016 URI reduction data; lower dose range acceptable for maintenance in non-athlete populations. Particularly valuable for travelers, parents of young children, and healthcare workers with high exposure.
Daily maintenance Anecdotal
- Dose
- 5-10 g/day powder
- Frequency
- daily
- Duration
- indefinite
Below the clinical effective dose for URI/gut endpoints but matches the typical community protocol. Reasonable for general immune/gut support when targeted therapeutic dose is not required. ARMRA's 1-3 g/day falls below even this floor.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
| Immune Function | 20g/day powder | 40-50% URI reduction in exercise-stressed athletes; salivary IgA maintenance |
| Gut Health | 20g/day powder | Prevents NSAID-induced and exercise-induced gut permeability increase |
| Recovery Repair | 20g/day powder | Immune support during heavy training; reduces training-related URI |
How this score is calculated →
Upside (1.60 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.8 | 0.700 | |
| Breadth of Benefits | 15% | 2.5 | 0.375 | |
| Evidence Quality | 25% | 3.0 | 0.750 | |
| Speed of Onset | 10% | 2.5 | 0.250 | |
| Durability | 10% | 1.5 | 0.150 | |
| Bioindividuality Upside | 15% | 2.5 | 0.375 | |
| Total | 2.600 |
Upside Rationale
Efficacy (2.8/5.0). URI reduction of 40-50 percent in exercise-stressed athletes is clinically meaningful, documented in the Jones 2016 (Sports Med) systematic review and echoed in the Davison 2021 meta-analysis. Gut barrier protection against NSAID and exercise-heat insults is well-demonstrated (Marchbank 2011, Playford 2001). The ceiling on the score comes from the null performance meta-analysis (Glowka 2021, Nutrients) and inconsistent body composition effects (Antonio 2001 positive, Duff 2014 null). Moderate efficacy overall: strong in the gut/immune lane, weak to absent in performance and body composition endpoints.
Breadth of Benefits (2.5/5.0). Two to three systems with credible evidence: immune function (URI reduction, salivary IgA maintenance per Shing 2007), gut permeability (Halasa 2017, Marchbank 2011, Playford 2001), and possibly body composition (mixed data). No credible cognitive, longevity, hormonal (oral IGF-1 is degraded), cardiovascular, or metabolic signals. Narrow relative to creatine or EAAs, but the domains that are covered are clinically meaningful for athletes, heavy NSAID users, frequent travelers, and chronically ill populations with gut-barrier dysfunction. Not a whole-body upgrade.
Evidence Quality (3.0/5.0). 30+ RCTs constitute a solid evidence base, with replication across multiple research groups for URI and immune endpoints (Jones, Shing, Brinkworth, Crooks). Two meta-analyses converge on gut and immune effects (Jones 2016, Davison 2021). Weaknesses: roughly 60 percent industry-funded, small sample sizes (most n under 40), concentrated in 3-4 primary research groups, and a definitively null performance meta-analysis. Pediatric GI data (Rathe 2014, Patel 2000) extends the evidence base. Per v0.5 evidence-integrity rules, moderate quality with no catastrophic burial signal.
Speed of Onset (2.5/5.0). Gut permeability protection shows within 14 days per Halasa 2017 and Marchbank 2011. URI reduction requires 8-12 weeks of loading at 20 g/day per Jones 2014 and 2015 trials. Athletic recovery benefits accrue gradually over 4-8 weeks. Subjective gut symptom improvement (bloating, stool consistency) is typically reported within 2-4 weeks at therapeutic dose. Slower than electrolytes or creatine, faster than longevity interventions. Users expecting next-day results consistently underdose and abandon the protocol before the URI signal is perceptible.
Durability (1.5/5.0). This is the dimensional weak spot. IgG in the gut lumen is transient, cleared in hours, and provides no memory-immunity effect because passive antibodies are not integrated into adaptive immunity. Growth factors are topically active during transit but do not accumulate systemically. Effects likely cease within days of stopping, similar to other substrate-class supplements without a storage depot. No half-life extension mechanism exists (unlike creatine phosphate muscle storage). Consistent daily dosing is required to maintain the clinical effect observed in trials.
Bioindividuality Upside (2.5/5.0). Most trial evidence comes from exercise-stressed athletes, not sedentary healthy adults. Benefit scales with immune stress: heavy training blocks, frequent viral exposure (parents of young children, healthcare workers, travelers), heavy NSAID use, and gut-compromised populations show the largest response. Dairy-allergic individuals are excluded entirely. Healthy sedentary adults on balanced diets show the smallest marginal benefit. The responder population is a minority of the general public, which caps this dimension at moderate.
Downside (0.55 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 1.5 | 0.450 | |
| Side Effect Profile | 15% | 2.0 | 0.300 | |
| Financial Cost | 5% | 2.5 | 0.125 | |
| Time/Effort Burden | 5% | 1.5 | 0.075 | |
| Opportunity Cost | 5% | 1.5 | 0.075 | |
| Dependency / Withdrawal | 15% | 1.0 | 0.150 | |
| Reversibility | 25% | 1.0 | 0.250 | |
| Total | 1.425 | |||
| Harm subtotal × 1.4 | 1.610 | |||
| Opportunity subtotal × 1.0 | 0.275 | |||
| Combined downside | 1.885 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.545 |
Downside Rationale
Safety Risk (1.5/5.0). Generally safe in trials up to 6 months at 10-60 g/day, which anchors the clean low-risk floor. The primary HARD contraindication is cow's milk allergy, where anaphylaxis risk is real and documented (at least one topical-use anaphylaxis case in the literature). Hormone-sensitive cancers warrant caution given trace steroid hormones in bovine dairy. No systemic IGF-1 elevation from oral dosing per PMC 2020 review, so the doping-adjacent concern is unfounded. Spray-dried products may carry a theoretical oxidized cholesterol concern (not clinically validated). Per v0.5 catastrophic-floor rules, no intrinsic floor triggered; anaphylaxis risk is audience-specific, not universal, and the overall safety profile in the indicated populations is clean.
Side Effect Profile (2.0/5.0). Bloating, gas, and loose stools are common in the first 1-2 weeks, typically self-resolving as the gut adapts to the IgG and growth factor load. Acne reports from the growth factor fraction in susceptible individuals (particularly those with known IGF-1/mTORC1 acne sensitivity or a history of dairy-driven breakouts). Moderate initial GI discomfort is the main complaint in community reports and trial adverse-event logs. No serious systemic side effects documented outside the allergy contraindication. Start at 5 g/day and titrate to 20 g over 1-2 weeks to minimize GI startup and identify individual tolerance.
Financial Cost (2.5/5.0). $30-80/month depending on brand and dose. ARMRA is premium-priced at roughly $0.87/serving for 1 g, which is expensive per gram of bioactive and below the clinical effective dose (20 g/day) that drives benefit in the Jones 2016 and Marchbank 2011 trials. Bulk powder from Kion, Sovereign Laboratories, or commodity brands runs $30-60/month at 10-20 g/day. Quality varies 3-fold across brands by IgG content, so cheapest-per-gram without a standardization label is false economy. Per v0.5 accessible-channel cost rules, scored at the accessible tier using the bulk powder floor, not the ARMRA branded premium.
Time/Effort Burden (1.5/5.0). Powder mixed in water, smoothie, or yogurt is the operational protocol. Twenty grams per day as powder is a single easy scoop split AM/PM with minimal ritual. As capsules it would require 20-40 pills per day, which is impractical at therapeutic dose and pushes most capsule users into sub-clinical dosing. No timing finesse required, no refrigeration (except liquid forms), no cycling or loading phase beyond the initial 2-week titration to avoid GI startup. Effort floor is near zero for powder users and significantly higher for capsule users, which is why the protocol section anchors on powder.
Opportunity Cost (1.5/5.0). Complements rather than competes with other immune-support tools (zinc, vitamin D, elderberry, LGG probiotics) and gut-barrier tools (L-glutamine, deglycyrrhizinated licorice, polyphenols). Minimal displacement of better-evidenced interventions. For athletes seeking both immune and gut benefit simultaneously, colostrum is arguably the single most evidence-backed option in one product. For non-athletes with no specific indication, general diet quality, sleep, and creatine would likely deliver more benefit per dollar. Per v0.5 audience-vs-indication rules, opportunity cost is low for the indicated populations and moderate for general wellness seekers.
Dependency/Withdrawal (1.0/5.0). No physiological dependency. No withdrawal. Colostrum is a nutritional substrate, not a pharmacologically active agent with receptor adaptation or neuroadaptation. Stopping produces no rebound or compensatory response. The gut returns to whatever baseline was present before supplementation. Per v0.5 dependency-vs-addiction framework, this is the substrate-class floor: nothing to taper, nothing to discontinue carefully, nothing that binds a user to the protocol beyond simple continued supplementation.
Reversibility (1.0/5.0). Fully reversible. All effects disappear within days of cessation as the transient IgG/IgA/growth factor bolus clears and the gut lumen returns to baseline tight-junction and microbial equilibrium. No structural, hormonal, or neurological changes that persist after stopping. Lower than interventions with any durable biological footprint (e.g., methylation or epigenetic interventions, long-acting injectables). Fully compatible with trialing, stopping, and restarting based on training cycles, sick-season exposure, or budget constraints, which is part of why the intervention is so forgiving for new users.
Verdict
Best for: Athletes under heavy training loads seeking immune protection and gut barrier support (Jones 2016 documents the URI endpoint). Heavy NSAID users (Playford 2001 gut protection). Travelers, parents of young children, and healthcare workers during sick season for immune modulation (10-20 g/day). Users with intensified training blocks or GI symptoms suggestive of permeability issues (20 g/day, 12-16 weeks per Halasa 2017). Choose IgG-standardized, true first-day, low-heat-processed, antibiotic-free pasture-sourced products (Kion, Sovereign Laboratories, or bulk equivalents meeting those criteria).
Avoid if: Cow's milk allergy (anaphylaxis risk; HARD contraindication). Hormone-sensitive cancer (trace steroid hormones in bovine products). Users seeking direct performance gains or significant muscle growth. Users expecting systemic IGF-1 elevation (oral IGF-1 is degraded).
A secondary consideration is supply-chain ethics and dairy welfare: bovine colostrum collection must not displace calf nutrition. Several brands source from surplus colostrum collected after calves have been fed; others do not. Industrial dairy sourcing also raises broader welfare concerns (housing, calf separation, antibiotic and hormone exposure). This is a sourcing-transparency question worth asking the manufacturer directly; it is not a score-penalty dimension but it is a relevant filter for ethically motivated buyers. The social media hype around colostrum (particularly ARMRA/TikTok-driven protocols) dramatically overstates the evidence and often runs at sub-therapeutic doses that would not have reproduced the Jones 2016 or Halasa 2017 endpoints.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| 💪 Immune Function | 7.0 | 40-50% URI reduction in exercise-stressed athletes (Jones 2014, 2015); salivary IgA maintenance (Shing 2007); IgG and lactoferrin are direct immune modulators. |
| 👍 Gut Health / Microbiome | 6.5 | Prevents NSAID-induced and exercise-induced gut permeability increase (Marchbank 2011, Playford 2001); IgG and lactoferrin support mucosal barrier. |
| ⚖️ Recovery / Repair | 5.0 | Immune support during heavy training reduces training-related illness; gut barrier protection supports recovery. |
| ○ Anti-Inflammatory | 4.0 | Lactoferrin is anti-inflammatory; PRPs modulate cytokine production; indirect evidence. |
| ○ Pediatric Use | 4.0 | Colostrum is inherently a neonatal food; some pediatric GI studies show benefit (Rathe 2014, Patel 2000). |
| ○ Skin / Beauty | 3.5 | Some community reports of skin improvement; growth factors (EGF, TGF-beta) have theoretical dermal benefit. |
| ○ Geriatric / Aging Population | 3.5 | Immune support beneficial for aging immune systems; gut barrier maintenance relevant. |
| ○ Endurance / Cardio | 3.0 | 60 g/day showed some cycling benefit (Coombes 2002) but dose is impractical; 20 g null for performance. |
| ○ Muscle Growth / Hypertrophy | 3.0 | Contains growth factors but oral IGF-1 does not reach systemic circulation; body comp data mixed. |
| ○ Wound Healing | 3.0 | Growth factors (EGF, TGF-beta) support wound healing; topical colostrum studied for wound care. |
| ○ Energy / Fatigue | 3.0 | Indirect via immune support reducing illness-related fatigue; not a direct energy substrate. |
Frequently Asked Questions
How does bovine colostrum actually work in the body?
Bovine colostrum acts almost entirely in the gut lumen, not systemically. The three main bioactive classes are immunoglobulins (IgG 20-200 mg/mL, IgA), lactoferrin (an iron-binding antimicrobial glycoprotein), and growth factors (TGF-beta, EGF, IGF-1, PRPs). IgG neutralizes pathogens locally, lactoferrin starves iron-dependent microbes, and growth factors stimulate epithelial repair. Crucially, oral IGF-1 is degraded in digestion and does NOT elevate systemic IGF-1, so the hormonal-doping concern is unfounded.
What is the difference between true first-day colostrum and transitional milk?
Colostrum is the first milk produced in the first 24-72 hours postpartum and contains 10-100x the bioactive concentration of mature milk. IgG drops from 20-200 mg/mL in first-day colostrum to under 1 mg/mL by day 4. Many commercial products blend in transitional or early-lactation milk to stretch yield, which dilutes potency. Premium products specify true first-day (first-milking) colostrum with standardized IgG content of 20-30 percent or higher by weight.
Does colostrum actually improve athletic performance?
Mostly no. Davison 2021 meta-analysis and Glowka 2021 (Nutrients) both show a null overall effect on exercise performance at practical doses. The one positive signal came from Coombes 2002, which required 60 g/day (roughly 12 scoops of powder) for a cycling benefit, which is impractical and prohibitively expensive. The real athletic value is indirect: 40-50 percent URI reduction in heavily training athletes (Jones 2016) and gut barrier protection during intensified training blocks keep athletes healthier, which preserves training continuity.
Can colostrum help heal leaky gut?
Halasa 2017 (Nutrients) documented reductions in intestinal permeability and stool zonulin in athletes on bovine colostrum. Playford 2001 and Marchbank 2011 showed prevention of NSAID-induced and exercise-induced gut permeability increase. The effect is driven by TGF-beta and EGF growth factors supporting tight-junction integrity, plus lactoferrin's antimicrobial action. Most users report symptom improvement (bloating, stool consistency) within 2-4 weeks at 20 g/day. It is not a cure for IBD or celiac disease, but it is a credible tool for permeability issues.
Does colostrum prevent colds and upper respiratory infections?
In exercise-stressed athletes, yes. Jones 2016 (Sports Med) systematic review documented 40-50 percent URI reduction at 20 g/day over 8-12 weeks. Shing 2007 showed salivary IgA maintenance during heavy training blocks. Evidence in non-athlete populations is weaker but mechanistically plausible. Effective doses are 10-20 g/day starting 2 weeks before sick season exposure; ARMRA's 1-3 g/day is below the effective range documented in the literature. Expect 4-8 weeks of loading before the URI reduction signal is clinically perceptible.
If I have dairy allergy, can I still take colostrum?
Cow's milk allergy (IgE-mediated) is a HARD contraindication; anaphylaxis risk is real and one topical-use case has been documented. Lactose intolerance is a different condition, and most lactose-intolerant users tolerate colostrum well because first-day colostrum is low in lactose. Casein-sensitive users should test conservatively. If you react to whey or casein with GI symptoms only (not hives or breathing issues), start with 1-2 g and titrate; true anaphylactic milk allergy means skip the category entirely and look at non-dairy immune tools.
Powder, capsule, or liquid: which form should I buy?
Powder is the default. It is the form used in nearly every RCT, it is dose-flexible, and it is the cheapest per gram. Capsules require 20-40 pills to reach 10-20 g, making therapeutic dosing impractical. Liquid and liposomal forms (Sovereign Laboratories Colostrum-LD) claim enhanced delivery but lack head-to-head RCT data and cost 3-5x more per gram. For the protocols in this report, use powder mixed in water, smoothie, or yogurt unless travel or taste constraints make capsules the only workable option.
Which colostrum brands are actually high quality and ethically sourced?
Look for four markers: true first-day (first-milking) colostrum, low-heat or flash pasteurization, antibiotic-free grass-fed herds, and IgG-standardized at 20-30 percent or higher by weight. Kion Colostrum and Sovereign Laboratories Colostrum-LD meet most criteria. ARMRA is premium-priced (roughly $0.87/serving for 1 g) and its 1-3 g/day protocol falls below the 10-20 g clinical effective dose, making it more expensive per gram of bioactive than bulk powder. Ethical sourcing (calf-first feeding, surplus collection) is a brand-level question worth asking directly.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimension shifts | New score |
|---|---|---|
| Large independent RCT confirms URI + gut benefits in non-athlete populations | Evidence 3.0 to 4.0 | 7.2 / 10 (Strong recommend) |
| Performance meta-analysis turns positive at 20 g dose | Efficacy 2.8 to 3.5 | 7.1 / 10 (Strong recommend) |
| Oxidized cholesterol concern validated in spray-dried products | Safety 1.5 to 2.5 | 6.1 / 10 (Worth trying) |
| Cochrane review downgrades immune evidence | Evidence 3.0 to 2.0, Efficacy 2.8 to 2.0 | 5.8 / 10 (Worth trying) |
Key Evidence Sources
- Jones AW, et al. 2016. Bovine colostrum supplementation and upper respiratory symptoms during exercise training: a systematic review and meta-analysis of randomised controlled trials. Sports Med. — Systematic review of URI and immune outcomes in exercise-stressed athletes. Foundational meta.
- Jones AW, et al. 2014. Bovine colostrum supplementation during running training increases intestinal permeability. Eur J Sport Sci. — 40-50% URI reduction in exercise-stressed athletes at 20 g/day.
- Jones AW, et al. 2015. Effects of bovine colostrum supplementation on upper respiratory illness in active males. J Sci Med Sport. — Reduced URI duration and severity in athletes.
- Davison G. 2021. The use of bovine colostrum in sport and exercise: an update on the scientific evidence. — Updated meta-analysis; immune and gut endpoints in athletes; confirms Jones 2016 effect size.
- Halasa M, et al. 2017. Oral supplementation with bovine colostrum decreases intestinal permeability and stool concentrations of zonulin in athletes. Nutrients. — Review of colostrum for gastrointestinal conditions; gut permeability reduction within 14 days.
- Brinkworth GD, Buckley JD. 2004. Oral bovine colostrum supplementation enhances buffer capacity but not rowing performance in elite female rowers. — Gut and immune endpoints in elite athletes; buffer capacity enhancement.
- Marchbank T, et al. 2011. The nutriceutical bovine colostrum truncates the increase in gut permeability caused by heavy exercise in athletes. Am J Physiol Gastrointest Liver Physiol. — Prevented exercise-induced gut permeability increase.
- Playford RJ, et al. 2001. Bovine colostrum is a health food supplement which prevents NSAID-induced gut damage. Gut. — Prevented NSAID-induced intestinal permeability increase.
- Playford RJ, et al. 1999. Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders. Am J Clin Nutr. — Protection against gastric injury.
- Glowka N, et al. 2021. Bovine colostrum supplementation and athletic performance: a systematic review and meta-analysis. Nutrients. — NULL overall effect on exercise performance.
- Antonio J, et al. 2001. The effects of bovine colostrum supplementation on body composition and exercise performance in active men and women. Nutrition. — Some lean mass gain; inconsistent across studies.
- Coombes JS, et al. 2002. Dose effects of oral bovine colostrum on physical work capacity in cyclists. Med Sci Sports Exerc. — Performance benefit at 60 g/day (impractical dose).
- Shing CM, et al. 2007. Effects of bovine colostrum supplementation on immune variables in highly trained cyclists. Br J Sports Med. — Maintained salivary IgA during heavy training.
- Rathe M, et al. 2014. Clinical applications of bovine colostrum therapy: a systematic review. Nutr Rev. — Clinical applications across pediatric and GI conditions.
- Patel K, Rana R. 2000 era. Pediatric and clinical applications of bovine colostrum. — Pediatric GI indications; infectious diarrhea and rotavirus.
- Oral colostrum does not increase circulating IGF-1. PMC 2020. — Oral IGF-1 degraded in digestion; no systemic IGF-1 elevation.
Other interventions for Immune Function
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. 5.0 is neutral (benefits and risks balance). Above 5 = benefits outweigh risks; below 5 = risks outweigh benefits.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.600 − 0.545 = 1.055
EV ranges from −5 to +5. Adding 7 shifts to 2–12, dividing by 12 normalizes to 0–1, then ×10 gives the 0–10 score.
Score = ((1.055 + 7) / 12) × 10 = 6.7 / 10
